Zoledronic acid may have anti-tumour properties

Share :
Published: 11 Mar 2009
Views: 14413
Dr Robert Coleman - Professor of Medical Oncology, University of Sheffield
Early results of the AZURE (Adjuvant Zoledronic Acid to Reduce Recurrence) trial suggest that zoledronic acid may have antitumor properties when combined with chemotherapy. Treatment was linked with a reduction in tumor size (20.5 mm vs. 30 mm), an increase in the complete response rate (10.9 percent vs. 5.8 percent) and a decrease in the number of patients requiring mastectomy (65.3 percent vs. 77.9 percent). Speaking at the 2008 San Antonio Breast Cancer Symposium.